45 results on '"Schrooten, Yoeri"'
Search Results
2. Phylogenetic Analysis of Hepatitis C Virus Infections in a Large Belgian Cohort Using Next-Generation Sequencing of Full-Length Genomes
3. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning
4. Horizontal gene transfer from human host to HIV-1 reverse transcriptase confers drug resistance and partly compensates for replication deficits
5. Antiretroviral drug resistance in HIV-1 therapy-naive patients in Cuba
6. High frequency of antiviral drug resistance and non-B subtypes in HIV-1 patients failing antiviral therapy in Cuba
7. Lessons in Developing a Full-Genome Next-Generation Sequencing Pipeline for Molecular Epidemiology of Hcv
8. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes
9. Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001
10. A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes
11. A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene
12. Molecular testing of multiple HIV-1 transmissions in a criminal case
13. Performance of the VERSANT ® HIV-1 Resistance Assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes
14. Additional file 3: Figure S1. of Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy
15. Additional file 4: Table S2. of Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy
16. Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy
17. Evaluation of the automatic editing tool RECall for HIV-1 pol and V3 loop sequences
18. Current levels of drug resistance among therapy-Native HIV infected patients have significant impact on treatment response
19. Performance of an In-House Human Immunodeficiency Virus Type 1 Genotyping System for Assessment of Drug Resistance in Cuba
20. Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic
21. High frequency of antiviral drug resistance and non-b subtypes in HIV-1 patients failing antiviral therapy in Cuba
22. Trends and Predictors of Transmitted Drug Resistance (TDR) and Clusters with TDR in a Local Belgian HIV-1 Epidemic
23. Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes
24. Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006.
25. Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006
26. Characterization of in vivo mutational patterns within HIV-1 group M viruses developed during long-term enfuvirtide therapy and after discontinuation on enfuvirtide
27. Prevalence of Transmitted Resistance in Newly Diagnosed HIV-Infected Individuals in Belgium Prospectively Collected Frim 2003 to 2005 is Significantly Higher Than 5%
28. Prospective Collection of Data on the Prevalence of Transmitted Resistance in Newly Diagnosed HIV-Infected Individuals in Belgium in 2004
29. Current levels of drug resistance among therapy-naive HIV-infected patients have significant impact on treatment response [1]
30. Performance of the VERSANT® HIV-1 Resistance Assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes
31. HIV-1 resistance testing using a commercial kit can be performed reliably without prior sequencing experience
32. Drug resistance among therapy-naïve HIV-infected patients studied by sequencing and VERSANT HIV-1 resistance assays (LiPA) has limited impact on treatment response
33. Novel Recombinant Virus Assay for Measuring Susceptibility of Human Immunodeficiency Virus Type 1 Group M Subtypes To Clinically Approved Drugs
34. No response to first-line tenofovir + lamivudine + efavirenz despite optimization according to baseline resistance testing: Impact of resistant minority variants on efficacy of low genetic barrier drugs
35. Prevalence and Epidemiology of HIV Type 1 Drug Resistance among Newly Diagnosed Therapy-Naive Patients in Belgium from 2003 to 2006
36. No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: Impact of resistant minority variants on efficacy of low genetic barrier drugs
37. Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory
38. Performance of the VERSANT®HIV-1 Resistance Assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes
39. A Combination of Poor Adherence and a Low Baseline Susceptibility Score is Highly Predictive for HAART Failure
40. Performance of the VERSANT® HIV-1 Resistance Assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes
41. Additional file 1: Table S1. of Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy
42. Additional file 1: Table S1. of Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy
43. Evaluation of the automatic editing tool RECall for HIV-1 pol and V3?loop sequences
44. A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failure
45. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.